STAAR Surgical (NASDAQ: STAA) reported Q1 EPS of ($0.07), $0.10 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $77.4 million versus the consensus estimate of $74.4 million.

GUIDANCE:

STAAR Surgical sees FY2024 revenue of $335-340 million, versus the consensus of $338.8 million.

Adjusted EBITDA of approximately $39 million and Adjusted EBITDA per diluted share of approximately $0.75, compared to prior outlook of Adjusted EBITDA of approximately $36 million and Adjusted EBITDA per diluted share of approximately $0.70.

The outlook above contemplates EVO ICL sales growth of approximately 7% in APAC, including 10% in China; 10% growth in the Americas, including 10% in the U.S.; and EMEA sales consistent with fiscal year 2023.

For earnings history and earnings-related data on STAAR Surgical (STAA) click here.